Versant Venture Management

Latest statistics and disclosures from Versant Venture Management's latest quarterly 13F-HR filing:

  • Versant Venture Management was a net seller of stock by $0.

Companies in the Versant Venture Management portfolio as of September 2017 quarter

Company (Ticker) Portfolio Weight Share Count Change in Shares Price
Audentes Therapeutics Inc Com stock 38.71 1.81M 28.15
Immune Design 17.69 2.21M 10.52
Achaogen 15.68 1.28M 16.08
Ocular Therapeutix 10.54 2.22M 6.25
Clovis Oncology 6.38 101855 82.32
Cymabay Therapeutics 6.29 1.05M 7.88
Second Sight Med Prods 4.10 4.49M 1.20
Opgen 0.60 2.55M 0.31

Past 13F-HR SEC Filings by Versant Venture Management

View All Filings